Arbutus Posts $59.1M Q3 Profit on Genevant Dividend, Expands Pfizer/BioNTech Patent Suits
ABUS is trading near its 52-week low of $3.5 (6.0% above the low) on light trading volume (0.3× avg).
Summary
Arbutus reported $59.1M of Q3 net income, driven mainly by a $67.3M Genevant dividend, and ended the quarter with $337.5M in cash and securities after its $230M buyback. The company also filed new LNP patent suits against Pfizer/BioNTech in Japan and amended its Canadian case.
Key Events · Earnings and Guidance · ABUS
-
Q3 Net Income of $59.1M
Net income was $59.1M, or $0.30 per basic and diluted share, versus a $7.7M net loss in Q3 2025; the swing was driven by a $67.3M Genevant dividend.
-
Cash Position of $337.5M
Cash, cash equivalents and marketable securities totaled $337.5M as of September 30, 2026, up from $91.5M at December 31, 2025, after the $230M tender offer.
-
New Pfizer/BioNTech Patent Suits
Arbutus and Genevant filed two Tokyo District Court suits (Japanese Patent Nos. 5,475,753 and 7,936,499) and amended the Canadian case to add Canadian Patent No. 2,767,127.
-
Moderna Appeal Argument Held
Expedited oral argument on the Moderna §1498 appeal was held November 5, 2026 at the Federal Circuit; a decision is forthcoming and could trigger the additional $1.3B contingent payment.
Analysis · ABUS · Life Sciences
The quarter's profit rests largely on a $67.3M Genevant dividend rather than operating income, so the headline number overstates the underlying business. More telling is the balance sheet: $337.5M of cash and securities after returning $230M to shareholders via the tender offer, which funds the imdusiran and AB-101 programs for years. Meanwhile, new Japan lawsuits and an amended Canadian case widen the Pfizer/BioNTech LNP enforcement effort, and the Federal Circuit's forthcoming ruling on the Moderna §1498 appeal could unlock the additional $1.3B contingent payment.
How filings like this one have moved
In the 30 days to Nov 10, 2026, 36.4% of the 3168 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ABUS was trading at $3.71 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $737M. The 52-week trading range was $3.50 to $5.45. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.